All posts tagged
More News! Allergan sees Patient Deaths, New Alzheimer’s Targets?
Allergan makes a deal with Editas to License CRISPR Programs for Eye Disease
The Patent Office has Spoken: What does it Mean for CRISPR in Europe?
UPDATE: No Clear Winner in the CRISPR Patent Battle
How much of a Gamble is Investing in CRISPR?
CRISPR Therapeutics applies to go Public in another Massive IPO
“CRISPR is highly fragmented, with too many approaches. We bring it all together”
CRISPR Patent war to End after the Discovery of a New Editing Protein other than Cas9?
Desktop Genetics bags €1.87M from top UK business angels to change how you manage your CRIPSR experiments
The 5 things outside Europe you need to know this week (Alphabet, Editas, Retrophin)
CRISPR Therapeutics reinforces its Team with Top Executives from Pfizer and McKinsey
German Viral Vector Producer SIRION pursues its American dream and opens in Boston
Labiotech UG, All Rights Reserved -
Send this to a friend